Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    The Role of Lactate Metabolism in Heart Failure and Cardiogenic Shock: Clinical Insights and Therapeutic Implications.

    Jan 29, 2025DOI: 10.1016/j.cardfail.2025.01.011Journal ArticleJCF

    Written by: Melana YuzefpolskayaSarah SchwartzAnnamaria LadanyiJacob AbrahamChris P GaleJonathan GrinsteinLiviu KleinDavid T MajureAnita PhancaoFarooq H SheikhPaolo C ColomboJames L JanuzziEzequiel J Molina

    Find these authors on Roon

    JG
    Dr. Jonathan Grinstein
    Advanced Heart Failure · UC

    Summary

    Heart failure (HF) is associated with poor prognosis, especially when it progresses to cardiogenic shock (CS), where survival rates substantially decline. A key area of interest is the role of blood lactate as a biomarker in these conditions. Lactate is produced under normal physiological conditions but increases with impaired tissue perfusion, a hallmark of HF and CS. Elevated lactate levels result from increased production, reduced clearance or both and are often associated with worse outcomes. Traditionally considered a byproduct of anaerobic metabolism, lactate is now recognized as an important energy substrate, particularly in myocardial tissue during periods of metabolic stress. Recent studies suggest that dynamic lactate monitoring, including lactate clearance (LC), may provide critical insights into patients' prognoses and responses to therapy. Serial measurements of lactate have been shown to predict survival in critically ill patients, including those with HF and CS. In CS, elevated lactate levels correlate with increased mortality risk, and LC is emerging as an important parameter in treatment protocols. Despite growing evidence of lactate's clinical relevance, research is needed to establish standardized thresholds and optimal monitoring timelines. Understanding the complexities of lactate metabolism and its role in HF and CS could lead to improved risk stratification and more personalized treatment approaches.
    JGDr. Jonathan Grinstein

    Dr. Jonathan Grinstein

    Cardiology · Advanced Heart Failure & Transplantation
    University of Chicago
    jonathang